XML 15 R36.htm IDEA: XBRL DOCUMENT
v3.20.1

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) | 3 Months Ended
--- | ---
Mar. 31, 2020 USD ($)
Property, Plant and Equipment [Line Items] |
Amortization of Intangible Assets | $ 745,511
Council License Agreement [Member] |
Property, Plant and Equipment [Line Items] |
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent | 50.00%
Maximum costs and expenses for post approval | $ 20,000,000
Council License Agreement Step 1 |
Property, Plant and Equipment [Line Items] |
Royalty (percent) | 5.00%
Council License Agreement Step 2 |
Property, Plant and Equipment [Line Items] |
Royalty (percent) | 10.00%
Council License Agreement Step 3 |
Property, Plant and Equipment [Line Items] |
Royalty (percent) | 15.00%
Vitamins and IMVEXXY [Member] |
Property, Plant and Equipment [Line Items] |
Shelf life of prescription products following product expiration | 24 months
BIJUVA and ANNOVERA [Member] |
Property, Plant and Equipment [Line Items] |
Shelf life of prescription products following product expiration | 18 months
ANNOVERA [Member] | Council License Agreement [Member] |
Property, Plant and Equipment [Line Items] |
Milestone payment upon FDA Approval | $ 20,000,000
Milestone payments (payment after release of first commercial batch) | 20,000,000
License rights acquired | $ 20,000,000
Minimum [Member] |
Property, Plant and Equipment [Line Items] |
Return period of unsalable prescription products | 6 months
Minimum [Member] | Council License Agreement Step 2 |
Property, Plant and Equipment [Line Items] |
Net sales amount per step-based royalty | $ 50,000,000
Minimum [Member] | Council License Agreement Step 3 |
Property, Plant and Equipment [Line Items] |
Net sales amount per step-based royalty | $ 150,000,000
Maximum [Member] |
Property, Plant and Equipment [Line Items] |
Return period of unsalable prescription products | 12 months
Maximum [Member] | Council License Agreement Step 1 |
Property, Plant and Equipment [Line Items] |
Net sales amount per step-based royalty | $ 50,000,000
Maximum [Member] | Council License Agreement Step 2 |
Property, Plant and Equipment [Line Items] |
Net sales amount per step-based royalty | $ 150,000,000

X
- Definition The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement. + References No definition available. + Details
Name: | txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payments upon FDA approval. + References No definition available. + Details
Name: | txmd_MilestonePaymentUponFDAApproval
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestone payments payable after release of first commercial batch. + References No definition available. + Details
Name: | txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The net sales amount as defined in license agreement for step-based royalty payments. + References No definition available. + Details
Name: | txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period the company accepts returns of unsalable prescription products from customers following product expiration. + References No definition available. + Details
Name: | txmd_ReturnPeriodOfUnsalablePrescriptionProducts
Namespace Prefix: | txmd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of the net sales to be paid as royalty per license agreement. + References No definition available. + Details
Name: | txmd_RoyaltyPercent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period shelf life of prescription products from date of manufacture. + References No definition available. + Details
Name: | txmd_ShelfLifeOfPrescriptionProducts
Namespace Prefix: | txmd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_AdjustmentForAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |